Related references
Note: Only part of the references are listed.Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?
Kati Choi et al.
INFLAMMATORY BOWEL DISEASES (2019)
Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis
Yinghong Wang et al.
INFLAMMATORY BOWEL DISEASES (2018)
Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
Yinghong Wang et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis
Hamzah Abu-Sbeih et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang et al.
NATURE MEDICINE (2018)
Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis
Daniel H. Johnson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study
Akbar K. Waljee et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2017)
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Viktoria Bergqvist et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
Eduard Cornelis Verschuren et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Krista Dubin et al.
NATURE COMMUNICATIONS (2016)
The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease
Esmail Abej et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Calprotectin as a diagnostic tool for inflammatory bowel diseases
Marianthi Chatzikonstantinou et al.
BIOMEDICAL REPORTS (2016)
Confocal Laser Endomicroscopy in Inflammatory Bowel Disease - A Systematic Review
Ditlev Nytoft Rasmussen et al.
JOURNAL OF CROHNS & COLITIS (2015)
The Modified Mayo Endoscopic Score (MMES): A New Index for the Assessment of Extension and Severity of Endoscopic Activity in Ulcerative Colitis Patients
Triana Lobaton et al.
JOURNAL OF CROHNS & COLITIS (2015)
Ipilimumab-induced colitis in patients with metastatic melanoma
Kara M. De Felice et al.
MELANOMA RESEARCH (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
Yan Feng et al.
CLINICAL CANCER RESEARCH (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting T-cell migration in inflammatory bowel disease
J. Marsal et al.
JOURNAL OF INTERNAL MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis
J. N. Hoes et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
